Myasthenia Gravis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Myasthenia Gravis (MG) is a relatively rare, acquired, chronic, autoimmune neuromuscular disease caused by an antibody-mediated blockade at the neuromuscular transmission, resulting in skeletal muscle weakness and rapid muscle fatigue. In many adults with MG, the thymus gland remains large. People with the disease typically have clusters of immune cells in their thymus gland and may develop thymomas (tumors of the thymus gland).
The myasthenia gravis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, pricing and reimbursement, leading marketed products with sales forecast, late-to-mid-stage pipeline products with phase transition success rate, and the likelihood of approval (LoA) for myasthenia gravis (MG).
Leading Marketed Drugs for Myasthenia Gravis
Some of the leading marketed drugs for myasthenia gravis are eculizumab, efgartigimod alfa, ravulizumab LA, neostigmine methylsulfate, and azathioprine.
Myasthenia Gravis Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for myasthenia gravis marketed drugs are enzyme inhibitor, receptor agonist, receptor antagonist, protein & peptide inhibitor, genes, nucleic acids & related components inhibitor, and enzyme activator. Enzyme inhibitor led the myasthenia gravis marketed drugs market in 2022.
Myasthenia Gravis Marketed Drugs Analysis, by Mechanism of Action, 2022 (%)
For more MoA insights into the myasthenia gravis marketed drugs, download a free report sample
Myasthenia Gravis Marketed Drugs Segmentation by Routes of Administration
The key RoA for myasthenia gravis marketed drugs are oral, injection, topical, suppository, and inhalational. Oral was the preferred route of administration in the myasthenia gravis marketed drugs market in 2022.
Myasthenia Gravis Marketed Drugs Analysis, by Routes of Administration, 2022 (%)
For more routes of administration insights into the myasthenia gravis marketed drugs, download a free report sample
Myasthenia Gravis Marketed Drugs Segmentation by Molecule Type
The majority of the marketed drugs for myasthenia gravis are small molecules. Biologic is another significant molecule type in the marketed drugs for myasthenia gravis.
Myasthenia Gravis Marketed Drugs Analysis, by Molecule Type, 2022 (%)
For more molecule type insights into the myasthenia gravis marketed drugs, download a free report sample
Leading Pipeline Drugs for Myasthenia Gravis
Some of the leading pipeline drugs of myasthenia gravis are Zilucoplan, Rozanolixizumab, Inebilizumab, Nipocalimab, Pozelimab, and Satralizumab.
Myasthenia Gravis Pipeline Drugs Segmentation by Mechanism of Action
The key mechanisms of action for myasthenia gravis pipeline drugs are enzyme inhibitor, receptor agonist, receptor antagonist, protein & peptide inhibitor, cytotoxic, ion channel blocker, biological factor inhibitor, enzyme activator, ligand inhibitor, and protein & peptide activator. Protein & peptide inhibitor was the leading MoA in the market in focus in 2022.
Myasthenia Gravis Pipeline Drugs Analysis, by Mechanisms of Action, 2022 (%)
For more MoA insights into the myasthenia gravis pipeline drugs, download a free report sample
Myasthenia Gravis Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for myasthenia gravis pipeline drugs are injection, oral, topical, and inhalational. Injection RoA led the market in 2022.
Myasthenia Gravis Pipeline Drugs Analysis, by Routes of Administration, 2022 (%)
For more routes of administration insights into the myasthenia gravis pipeline drugs, download a free report sample
Myasthenia Gravis Pipeline Drugs Segmentation by Molecule Type
The majority of the pipeline drugs for myasthenia gravis is biologic. The small molecule is another significant molecule type in the pipeline drugs for myasthenia gravis.
Myasthenia Gravis Pipeline Drugs Analysis, by Molecule Types, 2022 (%)
For more molecule type insights into the myasthenia gravis pipeline drugs, download a free report sample
Top Sponsors in the Myasthenia Gravis Marketed and Pipeline Drugs Market
Some of the top sponsors in the myasthenia gravis marketed and pipeline drugs market are Alexion Pharmaceuticals Inc, Argenx Inc, UCB SA, Immunovant Inc, Ra Pharmaceuticals Inc, Johnson & Johnson, Grifols SA, Aarhus University, and RemeGen Co Ltd. The clinical trial development in MG is dominated by commercial sponsors, with the Netherlands emerging as the key country for conducting Phase III trials in MG.
Myasthenia Gravis Marketed Drugs Report Overview
Key Mechanisms of Action | Enzyme Inhibitor, Receptor Agonist, Receptor Antagonist, Protein & Peptide Inhibitor, Genes, Nucleic Acids & Related Components Inhibitor, and Enzyme Activator |
Key Routes of Administration | Oral, Injection, Topical, Suppository, and Inhalational |
Key Molecule Types | Small Molecule and Biologic |
Myasthenia Gravis Pipeline Drugs Report Overview
Key Mechanisms of Action | Enzyme Inhibitor, Receptor Agonist, Receptor Antagonist, Protein & Peptide Inhibitor, Cytotoxic, Ion Channel Blocker, Biological Factor Inhibitor, Enzyme Activator, Ligand Inhibitor, and Protein & Peptide Activator |
Key Routes of Administration | Injection, Oral, Topical, and Inhalational |
Key Molecule Types | Small Molecule and Biologic |
Top Sponsors (Marketed and Pipeline Drugs) | Alexion Pharmaceuticals Inc, Argenx Inc, UCB SA, Immunovant Inc, Ra Pharmaceuticals Inc, Johnson & Johnson, Grifols SA, Aarhus University, and RemeGen Co Ltd.
|
Myasthenia Gravis Marketed Drugs MoA Outlook
- Enzyme Inhibitor
- Receptor Agonist
- Receptor Antagonist
- Protein & Peptide Inhibitor
- Genes, Nucleic Acids & Related Components Inhibitor
- Enzyme Activator
Myasthenia Gravis Marketed Drugs RoA Outlook
- Oral
- Injection
- Topical
- Suppository
- Inhalational
Myasthenia Gravis Marketed Drugs Molecule Types Outlook
- Small Molecule
- Biologic
Myasthenia Gravis Pipeline Drugs MoA Outlook
- Enzyme Inhibitor
- Receptor Agonist
- Receptor Antagonist
- Protein & Peptide Inhibitor
- Cytotoxic
- Ion Channel Blocker
- Biological Factor Inhibitor
- Enzyme Activator
- Ligand Inhibitor
- Protein & Peptide Activator
Myasthenia Gravis Pipeline Drugs RoA Outlook
- Injection
- Oral
- Topical
- Inhalational
Myasthenia Gravis Pipeline Drugs Molecule Types Outlook
- Small Molecule
- Biologic
Scope
GlobalData’s Myasthenia Gravis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Myasthenia Gravis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Myasthenia Gravis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for myasthenia gravis marketed drugs?
The key mechanisms of action for myasthenia gravis marketed drugs are enzyme inhibitor, receptor agonist, receptor antagonist, protein & peptide inhibitor, genes, nucleic acids & related components inhibitor, and enzyme activator.
-
What are the key routes of administration for myasthenia gravis marketed drugs?
The key routes of administration for myasthenia gravis marketed drugs are oral, injection, topical, suppository, and inhalational.
-
What are the key molecule types for myasthenia gravis marketed drugs?
The key molecule types for myasthenia gravis marketed drugs are small molecule and biologic.
-
What are the key mechanisms of action for myasthenia gravis pipeline drugs?
The key mechanisms of action in the myasthenia gravis pipeline drugs market are enzyme inhibitor, receptor agonist, receptor antagonist, protein & peptide inhibitor, cytotoxic, ion channel blocker, biological factor inhibitor, enzyme activator, ligand inhibitor, and protein & peptide activator.
-
What are the key routes of administration for myasthenia gravis pipeline drugs?
The key routes of administration in the myasthenia gravis pipeline drugs market are injection, oral, topical, and inhalational.
-
What are the key molecule types for myasthenia gravis pipeline drugs?
The key molecule types in the myasthenia gravis pipeline drugs market are small molecule and biologic.
-
Who are the top sponsors for the myasthenia gravis marketed and pipeline drugs market?
Some of the top sponsors in the myasthenia gravis marketed and pipeline drugs market are Alexion Pharmaceuticals Inc, Argenx Inc, UCB SA, Immunovant Inc, Ra Pharmaceuticals Inc, Johnson & Johnson, Grifols SA, Aarhus University, and RemeGen Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.